Financial health
as filed7.0/10
Is it financially healthy right now?
ROE -58%: lost 58¢ per shareholder dollar. Leverage 14%: owes 14¢ per asset dollar.
weight 45% of this tense · 70th percentile among 473 sector filers · read for itself
From the record
Return on equity: in the fiscal year ended 2025-12-31, CytoMed Therapeutics Limited lost about 58 cents for every dollar of shareholders' money. Leverage: it owed about 14 cents per dollar of assets, and net share issuance: its share count grew 0.9% over the year (the filed statements).
What it rests on
- what it owes per dollar of assetstop 23% of its family
- return on equitybottom 47% of its family
- the share count against the year beforetop 15% of its family
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Industry position
as filed4.5/10
How strong is its position in its industry?
bottom 45% of 315 in its family; net margin -1232%.
weight 22% of this tense · 45th percentile among 315 sector filers · read for its customers
From the record
CytoMed Therapeutics Limited's standing among 315 graded names in its industry family: revenue of $252 thousand in fiscal 2025 ranks in the bottom 11% by size; a net margin of -1232% ranks in the bottom 27%; revenue growth of 396.4% a year over the last 1 filed years ranks in the top 4% (its annual reports).
What it rests on
- revenue against the family$252,265bottom 11% of its family
- net margin-1232.0%bottom 27% of its family
- three-year revenue growth396.4%top 4% of its family
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Leadership
SI estimate5.0/10
What are the people in charge doing?
SI estimate 5.0/10, confidence 20 of 100 (family median).
weight 33% of this tense · 50th percentile among 371 sector filers · read for its shareholders
SI estimate Inferred, not read as filed
- Why it is an estimate
- It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2023-04-14 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 3.6 years and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
- What the record cannot read
- It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2023-04-14 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 3.6 years and cannot see past it; a floor under five years is not read as years in charge.
- How it was reasoned
- family median, 371 readings behind it.
- Confidence
- 20 of 100
- What would change it
- Its next annual report on file with the inputs replaces this estimate with the filed reading.
From the record
SI estimate, not a filed reading: CytoMed Therapeutics Limited's leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2023-04-14 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 3.6 years and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.